

## Product datasheet for **RC205582L1V**

### IFIT2 (NM\_001547) Human Tagged ORF Clone Lentiviral Particle

#### Product data:

Product Type:	Lentiviral Particles
Product Name:	IFIT2 (NM_001547) Human Tagged ORF Clone Lentiviral Particle
Symbol:	IFIT2
Synonyms:	cig42; G10P2; GARG-39; IFI-54; IFI-54K; IFI54; IFIT-2; ISG-54 K; ISG-54K; ISG54; P54
Mammalian Cell Selection:	None
Vector:	pLenti-C-Myc-DDK (PS100064)
Tag:	Myc-DDK
ACCN:	NM_001547
ORF Size:	1452 bp
ORF Nucleotide Sequence:	The ORF insert of this clone is exactly the same as(RC205582).
OTI Disclaimer:	The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. <a href="#">More info</a>
OTI Annotation:	This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
RefSeq:	<a href="#">NM_001547.3</a> , <a href="#">NP_001538.3</a>
RefSeq Size:	3505 bp
RefSeq ORF:	1419 bp
Locus ID:	3433
UniProt ID:	<a href="#">P09913</a>
Cytogenetics:	10q23.31
Domains:	TPR
MW:	56.2 kDa



[View online »](#)

**Gene Summary:**

IFN-induced antiviral protein which inhibits expression of viral messenger RNAs lacking 2'-O-methylation of the 5' cap. The ribose 2'-O-methylation would provide a molecular signature to distinguish between self and non-self mRNAs by the host during viral infection. Viruses evolved several ways to evade this restriction system such as encoding their own 2'-O-methylase for their mRNAs or by stealing host cap containing the 2'-O-methylation (cap snatching mechanism). Binds AU-rich viral RNAs, with or without 5' triphosphorylation, RNA-binding is required for antiviral activity. Can promote apoptosis.[UniProtKB/Swiss-Prot Function]